7 unchanged sentences
333-232369), as amended, originally filed with the SEC on June 26, 2019.
−Removed: Exhibit Number Description of document
4.3 Form of warrant to purchase Series F redeemable convertible preferred stock issued to Oxford Finance LLC and Silicon Valley Bank on March 31, 2017, incorporated by reference to Exhibit 4.6 of the Registrant’s Registration Statement on Form S-1 (File No.
2 unchanged sentences
333-232369), as amended, originally filed with the SEC on June 26, 2019.
+Added: Exhibit Number Description of document
4.5 Warrant to purchase common stock issued to SH Castle Biosciences, LLC on July 12, 2019, incorporated by reference to Exhibit 4.9 of the Registrant’s Registration Statement on Form S-1 (File No.
333-232369), as amended, originally filed with the SEC on June 26, 2019.
−Removed: 10.1# Fourth Amendment to Loan and Security Agreement, dated May 10, 2020, to Loan and Security Agreement, dated November 30, 2018, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank, incorporated by reference to Exhibit 10.24 of the Registrant’s Registration Statement on Form S-1 (File No.
−Removed: 333-239354) filed with the SEC on June 22, 2020.
−Removed: 10.2+ Separation Agreement dated May 29, 2020, by and between the Registrant and Federico A.
−Removed: Monzon, M.D., incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the SEC on June 2, 2020.
−Removed: 10.3+ Master Services Agreement dated May 29, 2020, by and between the Registrant and Genomic Path LLC., incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed with the SEC on June 2, 2020.
+Added: 10.1*+ Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan.
31.1* Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.
15 unchanged sentences
+ Indicates management contract or compensatory plan.
−Removed: # Certain portions of this exhibit (indicated by “[***]”) have been omitted as we have determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to us if publicly disclosed.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CASTLE BIOSCIENCES, INC.
−Removed: August 10, 2020 By:
+Added: November 9, 2020 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: August 10, 2020 By:
+Added: November 9, 2020 By:
/s/ Frank Stokes
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.